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ABSTRACT: The development of nano and micro delivery
systems (DS), so small in size, is growing in importance, such
as in drug targeting. In an era where nano is the new trend,
micro and nano materials are in the forefront of progress.
These systems can be produced by a diversity of methods.
However, the use of high-intensity ultrasound offers an easy
and versatile tool for nano- and microstructured materials that
are often unavailable by conventional methods. Similarly to the
synthesis methods that can be used, several starting materials
can be applied to produce particulate systems. In this review, the recent strategic development of DS is discussed with emphasis
on liposomes and polymer-based, specially protein-based, nanomedicine platforms for drug delivery. Among the variety of
applications that materials in the particulate form can have, the control release of drugs is probably the most prominent one, as
these have been in the forefront line of interest for biomedical applications. The basic concepts of sonochemical process
pertaining to DS are summarized as well as the role of sonochemical procedure to their preparation. The different applications of
these systems wrap up this review.
1. INTRODUCTION
Nano- and microparticles are particulate delivery systems (DS)
of nanometer or micrometer size ranges, respectively, and can
incorporate therapeutic agents, such as small drugs or even
macromolecules.1 The term microparticle refers to spherical
particles with diameters range between 0.1 and 100 μm.
Particles with diameter below 0.1 μm are called nanoparticles.2
The promising significance of nano- and microparticles in the
biomedical field and the needs of materials with biocompat-
ibility, biodegradability, and nontoxicity have propelled the
efforts for developing and optimizing new materials. Various
types of particles like solid lipid nanoparticles,3 micelles,4
liposomes,5 dendrimers,6 and polymers7 have been reported as
DS to encapsulate drugs and other bioactive agents (Figure 1).
Major advancements in delivery technology, such as particle
size, drug encapsulation, and targeting optimization, have been
achieved over the past few decades. Drug delivery, which takes
into consideration the carrier, the route of administration, and
the target, has evolved into a strategy of processes or devices
designed to enhance the efficacy of therapeutic agents through
controlled release. This may involve enhanced bioavailability,
improved therapeutic index (ratio between the efficacy of the
drug and its undesirable side effects), or improved patient
acceptance or compliance. In fact, the administration of a drug
in a DS influences their parameters, in particular concerning the
pharmacokinetics and pharmacodynamics, which, in turn, affect
their therapeutic index.8,9 Thus, the DS can increase the
bioavailability of drugs and decrease their toxic effects, leading
to an increase in therapeutic index (Figure 2). Additionally,
they can vehicular and release the drugs in a target cell, thereby
decreasing the dose required to observe certain action,
minimizing the side effects.10
The need of developing new DS at nano and microscaled
materials is paralleled by attempts to optimize or develop new
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Figure 1. Types of nano- and microtechnology used for delivery
purposes. The major components are either lipids or polymers. The
black and gray axis represents the diameter of technology. Reproduced
with permission from ref 8. Copyright 2006 Springer.
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techniques to produce them. Therefore, numerous protocols
exist for synthesizing nano and microparticles based on the type
of drug used and the desired delivery route. Among a variety of
approaches, the utilization of ultrasound for material synthesis
has been extensively studied, and now is positioned as one of
the most powerful tools in nano and micro structured materials
synthesis.11 Once a protocol is chosen, the parameters must be
tailored, such as time, agitation and geometry of reactor, to
create the best possible characteristics for the developed
particles.
In this review, the ultrasound-assisted synthetic methods
(sonochemistry) will be discussed to provide a fundamental
understanding of their basic principles and to demonstrate the
powerful and unique aspects of ultrasound in nano and micro
structured materials synthesis. This review also focuses on the
materials-based drug delivery platform, highlighting the use of
phospholipids and proteins. Finally, it will be pointing out to
areas requiring focused effort to arrive at an understanding of
applications of these devices as delivery systems in different
biomedical applications.
2. SONOCHEMISTRY
Sonochemistry is the research area in which molecules can
undergo a chemical reaction due to the application of powerful
ultrasound radiation (20 kHz−10 MHz).12 Considering typical
sound velocities in liquids of ≈1500 m s−1, acoustic
wavelengths range from 10 to 10−4 cm, which is far above
molecular and atomic dimensions.13 Thus, no direct molecular
level interaction between ultrasound and chemical species take
place. Instead, acoustic cavitation, driven by high-intensity
ultrasound, accounts for the chemical effects of ultrasound.14
Ultrasonic irradiation differs from traditional energy sources in
duration, pressure, and energy per molecule.15 Cavitation
occurs over a very wide range of frequencies, from tens of hertz
to tens of megahertz; above that frequency regime, the intrinsic
viscosity of liquids prevents cavitation from occurring. Most
high-intensity ultrasonic horns operate at 20 or 40 kHz, most
cleaning baths near 40 kHz, and there is specialized equipment
available in the few hundred kilohertz to few megahertz
regime.12,16 In general, physical effects of ultrasound (e.g.,
emulsification and surface damage) are more dominant at lower
frequencies, whereas cavitational heating of collapsing bubbles
occurs over the full frequency range. Acoustic cavitation
appears in the liquids at high and moderate intensities of
ultrasonic irradiation. The minimum power intensity required
for ultrasonic cavitation increases with the increase of the
frequency of ultrasound.17 When sonicating liquids at high
intensities, the sound waves that propagate into the liquid
media result in alternating high-pressure (compression) and
low-pressure (rarefaction) cycles, with rates depending on the
frequency. The liquid expands during the expansion by the
sound field (“negative pressure”, low pressure). This results in
rapid growth of the weak sites of the liquid predominantly
containing dissolved gases (“cavitation nuclei”), thus producing
vapor- and gas-filled cavities or microbubbles.18 Then, the
liquid compresses during the compression phase of the sound
field (“positive pressure”, high pressure). The bubbles continue
to grow during the negative/positive cycles of the ultrasound
until reaching a critical diameter (Figure 3), which depends on
ultrasound frequency and nature of the liquid. This “critical”
bubble is mostly filled with gases and vapor and thus unable to
provide stiffness. The compression of bubbles occurring during
cavitation is more rapid than thermal transport and generates
localized hot spots. The compression of bubbles during
cavitation leads to the enormous concentration of energy
within the small volume of the collapsed bubble. The oscillating
bubbles can accumulate ultrasonic energy effectively while
growing to a certain size (typically tens of millimeters).19
Under the right conditions, a bubble can overgrow and
subsequently collapse, releasing the concentrated energy stored
in the bubble within a very short time (with a heating and
cooling rate of >1010 K s−1). This cavitational implosion is very
localized and transient with a temperature of ≈5000 K and a
pressure of ≈1000 bar.20
The chemical effects of ultrasound were explored for many
years, specially in water.22−26 Ultrasonic irradiation of aqueous
liquids generates free radicals and the formation of free radicals
by sonolysis of water has been particularly well-studied. Primary
sonolysis products in water are hydrogen radicals (H•) and
hydroxyl radicals (•OH) (eq 1).27 These radicals can
recombine to return to their original form or combine to
produce hydrogen (H2) and hydrogen peroxide (H2O2) (eqs 2
and 3). They can also produce hydroperoxyl radicals (HO2
•) by
combination with oxygen (O2). These strong oxidants as well




Figure 2. Release profile of conventional formulation (1) and drug
delivery systems (DDS) (2) over time.
Figure 3. Schematic representation of transient acoustic cavitation.
Reproduced with permission from ref 21. Copyright 1995 Cambridge
University Press.
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2.1. Sonoproduction of Nano- and Microstructured
Materials. The ultrasonic irradiation, compared to traditional
energy sources, provides rather unusual reaction conditions (a
short duration of extremely high temperatures and pressures in
liquids) that cannot be realized by other methods.18 Major
developments in nanotechnology have been achieved, by
sonochemistry methodology, synthesizing different nano- and
microstructured materials. A diverse set of applications of
ultrasound have been explored to obtain such different
materials.
Table 1 summarizes the most frequently used materials for
the synthesis of nano- and microstructures by the sonochemical
method.
Among all the materials used, liposomes and protein particles
are widely used in biomedical field. For this reason, this review
details the latest development of liposomes and protein nano-
and microparticles DS and their potential applications.
3. LIPOSOMES
Liposomes are highly versatile structures for research
therapeutic and analytical applications.89
Since Bangham et al.90 described for the first time the
preparation of liposomes, they have been often used as
membrane model systems to reveal the basic nature of cell
membranes. In 1971, Gregoriadis91 proposed for the first time
the use of liposomes as drug carrier systems, describing the
conditions for the entrapment of Aspergillus niger amylogluco-
sidase (EC 3.2.1.3) and 131I-labeled albumin into liposomes
composed of phosphatidylcholine, cholesterol, and dicetyl
phosphate.
The unique physicochemical properties of liposomes coupled
with a structural versatility explain the great potential of these
resources organized as membrane models and vectors of drugs,
which translate into huge numbers of studies achieved with
these systems.92
According to the parameters previously described, it is
important to state the essential physicochemical characteristics
along with their classification. Furthermore, an overview of
liposomes preparation using the sonochemical methodology
will be highlighted as well as their applications as DS.
3.1. Physicochemical Considerations. Phospholipids are
the major structural components of biological membranes.
They are amphiphatic molecules in which a glycerol bridge
links a pair of hydrophobic chains and an hydrophilic polar
headgroup, phosphocholine.31 The hydrophobic part consists
of two hydrocarbon chains of saturated or unsaturated fatty
acids, which esterify the same number of hydroxyl groups of
glycerol, and each chain can present 10−28 carbon atoms.93
Amphipathic lipids have the ability to spontaneously form
bilayer aggregates when dispersed in an aqueous solution,
involving within a certain volume of solvent. These structures
may consist of one or several concentric membranes, varying in
size from 20 nm to a few micrometers in diameter, with a
membrane thickness approximately equal to 4 nm.31
Phospholipids are abundant in nature and certainly the most
used in the preparation of liposomes are those containing
choline.33 These are called lecithin or phosphatidylcholine (of
the “lekithos”, a Greek word meaning egg yolk) and are dipolar
molecules at physiological pH, with the quaternary ammonium
group presenting a positive charge and a negative charge in the
phosphate group.94
Lecithin from natural sources, as extracted from egg yolk or
soybean, is a mixture of several molecules with carbonaceous
chains of different lengths and different degrees of saturation.
The most abundant fatty acid in lecithin from egg yolk is
palmitic acid (35.3%), followed by oleic acid.31 However,
lecithin can also be obtained by synthesis, presenting a well-
defined composition, particularly with respect to acyl chains,
which can be obtained from saturated or unsaturated
hydrocarbon chains, with greater or lesser number of carbon
atoms, equal or different. This type of phospholipid, such as
dipalmitoylphosphatidylcholine (DPPC) or dimyristoylphos-
phatidylcholine (DMPC), can be easily characterized for
various thermodynamic parameters, compared to the hetero-
geneous populations that are in the natural phospholipids.33
Besides phospholipids, the liposomes can also include other
molecules, also present in natural membranes, such as
cholesterol.95 Cholesterol improves the fluidity of the
membrane bilayer, reduces the permeability of water-soluble
molecules through the membrane, and improves the stability of
the bilayer membrane in the presence of biological fluids, such
as blood/plasma.96
One of the main physical characteristics of lipid bilayers is
the existence of a temperature where the organization of
phospholipids changes. Thus, for different values of temper-
ature, lipid bilayers can present itself in two distinct
thermodynamically phases, occurring transition from one
phase to another by varying the temperature.31 Therefore, the
lipid bilayers can be presented in a phase of great order,
designated by solid-gel state, and for higher temperatures, a
more fluid phase called liquid crystal,31,33 as shown schemati-
cally in Figure 4.
Table 1. Overview of the Materials Used To Achieve
Different Nano- and Microstructures by Sonoproductiona
material type
phospholipids liposomes (small unilamellar vesicles and large unilamellar
vesicles)28−42
triacylglycerols solid lipid nanoparticles43,44
polymers protein,45−70 chitosan,71 polyglutamate/
polyethyleneimine/poly(acrylic acid),72 poly(vinyl
alcohol),73 poly(allylamine hydrochloride)/





nanowires,85,86 mesoporous and amorphous
nanostructured87,88
aInformation was compiled, in the scope of this review, from refs 15
and 28−88.
Figure 4. Schematic representation of the organizational structure
presented by the hydrocarbon chains of phospholipids in the gel−solid
state and liquid crystal. ΔT corresponds to the variation of
temperature.
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The temperature of transition from one stage to another is
called temperature of phase transition (Tc) and is specific to a
particular lipid. Thus, when the temperature of the system is
lower than Tc of the phospholipid components of a given
bilayer, this presents an ordered structure where the hydro-
carbon chains are in an extended conformation and tight
packaged, and the freedom of movement is severely restricted.
Above Tc, increases the mobility of the acyclic chains in the
membrane, the area occupied by each phospholipid molecule is
higher and the bilayer thickness decreases.31,33
The influence of hydrocarbon chain length and unsaturation
(as well as headgroup) on the value of Tc for a membrane
composed of different phospholipids is considerable. In general,
increasing the chain length or the saturation of the chains
increases the transition temperature. For a homogeneous
composition of membranes is possible to state a value of the
phase transition temperature. However, for mixtures of
phospholipids, Tc comprises a range of temperatures. The
width of this interval depends strongly on the lipid composition
and can cover more than 10 °C or even be absent in certain
mixtures of lipids, for example, in the presence of high
concentrations of cholesterol (50%). The Tc described for
DMPC is 23.5 °C and for DPPC is 41.4 °C, while the egg yolk
phosphatidylcholine (EPC), an heterogeneous mixture, has a
transition temperature of −15 to −7 °C.31,33
An understanding of phase transitions and fluidity of
phospholipids membranes is important both in the manufacture
and exploitation of liposomes, since the phase behavior of a
liposome membrane determines such properties as perme-
ability, fusion, aggregation, and protein biding, all of which can
markedly affect the stability of liposomes and their behavior in
biological systems.31,97
Another important feature inherent to the membrane
structure is its permeability, which is highly dependent on the
dynamics and thermodynamics of membrane phase.33 The
degree of diffusion of molecules and ions through the bilayer
varies considerably. The bilayers are sufficiently permeable to
hydrophobic molecules but may constitute a barrier to
hydrophilic molecules. Thus, compounds that are more
hydrophilic can pass through the membrane, but more slowly,
or else through typical channels in the membrane. The water
and ions such as calcium ions, potassium, sodium, and chlorine,
for example, pass through the membrane channels (proteins),
which control the entry and exit of these compounds in the
cell.31
3.2. Classification of Liposomes. Apart from their
chemical constituents, liposomes can be characterized based
on their number of lipid bilayers (lamellae) and size. Thus,
without any further processing, the dispersion of phospholipids
in water leads to a polydisperse population known as
multilamellar vesicles (MLVs), whose sizes are usually ranging
from 0.4 and 3.5 μm of diameter.31 Each vesicle consists of
multiple lipid bilayers (around five or more) concentrically
arranged, between which there is a fraction of internal aqueous
medium. The MLVs were used in early studies being the
vesicles with the most immediate preparation. The liposomes
formed by a single bilayer are called large unilamellar vesicles
(LUVs) if its size exceeds 50 nm, according to some authors,93
or 100 nm, according to others.96 The small unilamellar vesicles
(SUVs) are characterized by approximate diameters from 25 to
50 nm and unilamellar vesicles of intermediate size
(intermediate sized unilamellar vesicles (IUVs)) for inter-
mediate sizes.31 In addition to these unilamellar vesicles, it
should be also considered the giant unilamellar vesicles
(GUVs), larger than 1 μm and can reach the tens of
micrometers size, comparable to size of a eukaryotic cell
(10−100 μm in diameter31). Figure 5 represents the types of
liposomes described.
According to the aim of study, it should be selected the more
suitable type of liposomes, usually MLVs, LUVs, or SUVs. For
example, in the study of structural, dynamic, and thermody-
namic properties of membranes, in which the sensitivity can
often be a problem, normally it is preferred the MLVs, due to
its higher lipid concentration. Contrariwise, unilamellar
structures are chosen, particularly the LUVs, in studies of
membrane permeability and the roles of proteins. SUVs, due to
the high curvature, present anomalies in the packaging of lipids
that make them susceptible to degradation in the presence of
biological molecules.98 Additionally, LUVs have a volume
fraction for encapsulation much larger than SUVs for the same
lipid concentration.5
When they are applied as vehicles, multilamellar structures
are usually preferred in the case of hydrophobic molecules to be
encapsulated, while LUVs are more appropriate for the
hydrophilic molecules, since they have a large volume/surface.
Conversely, the MLVs provide a more sustained drug release
than LUVs, as their membranes are being gradually degraded at
the site of action.31,33 However, if it is desirable rapid delivery
of the drugs, the LUVs are the most suitable ones.99 For the
surface studies there is a need of large surface/volume ratio, and
the obviously preferred choice are SUVs, while GUVs are too
fragile for most applications. Although, these vesicles are very
useful for studies of basic features, such as elasticity,
permeability, and tensile strength of bilayers, in which the
optical microscope is the main method used.5
3.3. Preparation of Liposomes. The widespread use of
liposomes for various purposes has created the need to develop
preparation methods, which should be efficient, reproducible,
and with the greatest simplicity. The methods of preparation of
liposomes, currently available, are diverse and may have
numerous variants. The classic preparation of liposomes,
initiated by Alec Bangham in 1965, and used nowadays, is
entitled by the thin film hydration method.100 This preparation
process may undergo some changes, particularly regarding the
organic solvent used and the possible addition of glass beads,
from the drying of lipid and parameters agitation, such as time,
intensity, mode of agitation, and temperature.33 However, this
method always leads to the formation of MLVs, which are very
heterogeneous regarding size, shape, and number of lipid
bilayers, and a small percentage of LUVs and SUVs.101
Therefore, it is necessary to submit MLVs to further processes,
when vesicles with specific sizes are needed. These processes
include mechanical, chemical, or electrostatic methods that
allow obtaining unilamellar liposomes. There are also methods
Figure 5. Schematic representation of the different types of liposomes
classified according to the size and number of lipid bilayers. Each line
represents a lipid bilayer.
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that use already preformed vesicles, SUVs to form mainly
LUVs, small MLVs, and GUVs. These methods are based
primarily on melting, freezing, and thawing or dehydration/
rehydration of liposomes. However, the most frequently used
methods are mechanical, and the most widespread of these are
the sonication and extrusion, although the homogenization and
French press can also be applied.28,31,33
The major advantages of the extrusion technique are directly
related with a possibility to make homogeneous populations of
LUVs in the size range of 40−150 nm. Nevertheless, a
drawback associated with this type of equipment is the
inconvenience experienced with the clog of pores in the
membrane particularly when processing concentrated suspen-
sions and/or the liposomes sizes are substantially greater than
the membrane pores sizes.102
Sonication is also one of the most popular methods to
prepare liposomes from the aqueous dispersion of phospholi-
pids, which has been used from the beginning of the study of
liposomes.28 Since that several studies have been performed
with ultrasound in order to obtain unilamellar vesicles with
defined sizes.
Finer and co-workers29 found that the collisions produced by
ultrasound led to complete disruption of the multilamellar
particles, with the formation of short-lived bilayer fragments or
other forms of small lecithin aggregates. These fragments then
reaggregate to form single-shelled vesicles of roughly uniform
size.
Woodbury and co-workers performed a study where the
main goal was to obtain a detailed characterization of the
various lipid suspensions produced by using different sonication
times.35 They had shown that mildly sonicated liposomes
generally have a bimodal distribution and are not well described
by single mean.
The studies of treatment time of ultrasound have been also
performed by Maulucci et al.34 The results indicate that the
lipid film, upon sonication, forms LUVs, which then
progressively reduce their size when increasing the sonication
time. At shorter sonication time, the total energy transferred by
sonication was not sufficient to reduce MLVs, and if the
treatment is too long, the vesicles are damaged by the
generated free radicals. Therefore, an optimal sonication time
must be determined for the specific use of the vesicles.
The size changes of liposomes, as well as the polydispersity
and lamellarity of the systems as a function of the ultrasound
power applied, were also studied.36 They concluded that the
increase of ultrasound power decreases the number of lamellae,
the vesicle size, and the polydispersity, obtaining an
homogeneous distribution of lipid vesicles.
Later, the effect of sonication and freezing−thawing on the
aggregate size and dynamic surface tension of aqueous DPPC
dispersions was studied.37 When DPPC dispersions were
prepared using extensive sonication, they form vesicles that
were quite clear, transparent, and stable for at least 30 days.
The average dispersed vesicles diameter was 80 nm in water
and 90 nm in standard phosphate saline buffer. After a freeze−
thaw cycle, this dispersion became turbid, and precipitates of
coagulated vesicles were observed with large particles of average
size of 1.5 × 103 nm. The vesicle coagulation is due to the local
salt concentration increase during the freezing of water. This
dispersion had shown much higher equilibrium and dynamic
surface tension than those before freezing. When this freeze−
thawed dispersion was subjected to a resonication at 55 °C,
smaller vesicles with sizes of 70 nm were produced and a lower
surface tension behavior was restored as before freezing.37
Recently, Richardson and co-workers38 explore also the role
of cavitation, using a bath sonicator, in manipulating liposome
size. They hypothesize that ultrasonic cavitation phenomena
play a key role in altering the size distribution of liposomes
processed in an ultrasonic bath. They manipulate the size of
liposomes by correlating changes in liposome size with
cavitation emissions at various acoustic intensities and static
pressures. The authors developed a mathematical model based
on the Rayleigh−Plesset equation of bubble dynamics and
principles of acoustic microstreaming to estimate the shear field
magnitude around an oscillating bubble. This model predicts
the ultrasound intensities and pressures needed to create shear
fields sufficient to cause liposome size change. The results of
mathematical models show that stable (noncollapse) cavitation
can generate sufficient shear through acoustic microstreaming
to reduce liposome size. Moreover, these mathematical models
of acoustic microstreaming can qualitatively explain the effects
of pressure and acoustic intensity on liposome size reduction.
Richardson and co-workers proved that the microstreaming
around oscillating bubbles, and not necessarily collapse
cavitation events, create shear sufficient to reduce the size of
the liposomes during ultrasonic processing.
Besides various powers, it was also study the influence of
different ranges of frequencies (43−480 kHz) to obtain
liposomes prepared with L-α-dilauroylphosphatidylcholine. It
was observed a faster reduction of the mean size of liposome
when a lower frequency was used.39 The effect of frequency on
the size reduction of liposome can be related to the strength of
cavitation caused by the difference in the bubble dynamics. The
amplitude of the oscillation of a cavitation bubble is larger at
lower frequency because the bubble experiences longer time of
negative pressure to glow larger.103 The impulsive shock wave
and the microjet stream created by a bubble are thus stronger at
the lower frequency, and consequently a size reduction of
liposome was faster.
More recent studies performed by Silva et al.40,41 reported
the importance of the different parameters of sonication, such
as power delivery, time, and distance from ultrasound tip to
base of reactor, when a transducer of 20 kHz is used to obtain
LUVs. The data obtained reveal the importance of LUVs
preparation in the nodal (lower production of •OH) and
antinodal (higher production of •OH) horn position of
ultrasound sources.
Another approach based on the parameters previously
mentioned40,41 was used to obtain the reduction of liposome
sizes prepared with internal wool lipids (IWLs).42
3.4. Stability of Liposomes. Over time, the liposomes can
undergo several types of changes, including physical and
chemical modifications.90 However, if prepared and stored
under very specific conditions, the occurrence of these changes
can be minimized. A stability study program must include the
product characterization.
Average size distribution of liposomes determined at the time
of their preparation can change upon their storage.
Independently of the preparation method, liposomes tend to
fuse and grow into bigger vesicles, which is a thermodynami-
cally more favorable state. Since this phenomenon may occur
mainly at the Tc, it is advisible to store the suspensions of
liposomes at a temperature different from that. Additionally, it
can be advantageous to include a sufficient proportion of
cholesterol into the membrane to reduce or eliminate the phase
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transition, particularly if it occurs in a temperature range near
which the liposomes are stored or handled. The macroscopic
aspect, average size, and size distribution are important
parameters to evaluate and can be obtained by examination
of the suspension or by using the photon correlation
spectroscopy (PCS) and/or electron microscopy.31,33,41,96
Chemically, phospholipids are susceptible to oxidation and
hydrolysis reactions, which can be accelerated by the free
radicals formed in the cavitation bubbles during the preparation
of the sonicated phospholipid suspension.32 Although,
according to Kruus et al.,104 the formation of free radicals is
not a major problem when low frequencies (≈20 kHz) and
short sonication times (≈20 min) are used. Rabinovich-Guilatt
et al.105 proved that the use of a temperature of 50 °C over 24 h
induces only 1.6% of phosphocholine hydrolysis.
Although, the most susceptible to degradation are lipids
containing double bonds, since the unsaturation permits
delocalization of the remaining unpaired electron along the
lipid chain and lowers the energy of this state (and hence
increases the probability of it being formed). The polyunsatu-
rated fats are thus particularly susceptible to oxidative
degradation.31,33 The oxidative degradation of the lipids in
general can be minimized by protecting the lipid preparations
from light, by adding antioxidants, or by producing the product
under nitrogen or argon environment.33,96,106,107 The hydrol-
ysis of phospholipids leads to the formation of lysophospho-
lipids and free fatty acids.108−110 The presence of lysophos-
pholipids enhances the permeability of liposomes, and thus it is
essential to keep its level to a minimum in a given
preparation.110 Hydrolysis is strongly affected by temperature
and pH. In fact, this degenerative chemical process can occur to
a lesser extent at low temperatures and pH values close to
neutrality.31 On the other hand, the use of lipids that contain
ether linkages instead of ester, such as those found in the
membranes of halophilic bacteria, completely avoids the
hydrolysis reactions.31,111,112
Other factors to be taken into consideration prior to starting
a stability study are the formulation factors and environmental
conditions, which may influence the stability of liposomes.
Influences of formulation factors such as pH, buffer species,
ionic strength, and solvent system play a major role in
stabilizing a liposome formulation.96
3.5. Liposomes as Delivery Systems. The ability of
liposomes to dissolve, protect, and drive water or fat soluble
drugs as well as its biocompatibility with cell membranes and
the possibility of adding certain ligands to their surface
achieving a particular cell type were the main reasons for
their implementation systems as carriers of drugs in cosmetic,
pharmacology, and medicine.33,92,113,114 One of the main
advantages of using liposomes as carriers is the easy drug
incorporation, independently of their charge or molecular
weight, and the accommodation of substances with very
different polarity characteristics on the same system114,115
(Figure 6).
As a pharmaceutical formulation, the main advantages
conferred by liposome encapsulation of drugs are increased
solubility of lipid soluble drugs and the protection granted by
these systems to hydrolysis of the drugs, caused for example by
the action of degenerative enzymes, adverse pH, and action of
light.33
The application of liposomes in vivo is limited by its retention
at the level of the reticuloendothelial system (RES). Generally,
liposomes sizes for use in parenteral administration are between
about 0.1 and 0.3 μm.116 In fact, liposomes in the bloodstream
are quickly captured by the macrophages as well as the liver,
spleen, lymph nodes, lungs, and bone marrow, which have the
function of processing the foreign agents that enter in the
body.117 Thus, the half-life in plasma of liposomes can be
reduced to few minutes. The problems led to the development
of liposomes, with the inclusion of certain molecules in their
outer layer, with new transport options in order to prevent their
elimination by the RES. Indeed, the physical characteristics and
composition of liposomes affects their capture by the RES, such
as the size and fluidity. Therefore, larger liposomes are captured
more quickly as well as the more rigid liposomes due to its
constitution.118 One way to going through this problem is
coating liposomal vesicles with a hydrophilic polymer, such as
poly(ethylene glycol) (PEG), which reduces uptake by the
RES.119−121 As a result, coated liposomes remain in circulation
longer than conventional liposomes. Additionally, incorporating
targeting ligands on the surface of the liposomes, it is possible
to direct them to certain organs. For example, an association
with folic acid or antibodies, which are specific to particular
cell.117,122−126 The modified liposomes are generically called
stealth liposomes and may increase 100 times the half-life.121,127
4. POLYMERIC PARTICLES
It has recently become a trend to develop new and suitable
biomaterials, due to their bioavailability, biocompatibility, and
biodegradability coupled with low toxicity being the usefulness
of polymers in drug delivery systems (DDS) well established.
Continued improvement and accelerating research and
development in polymeric materials have played a vital role
in the progress of most controlled-release technologies. In the
past 25 years, there has been a considerable increase interest in
this technology, as is shown by the increasing number of
publications and patents in the area of controlled drug-release
systems using synthetic as well as naturally occurring polymeric
materials.128
The furthermost nano- and microparticle formulations are
effectively based on nano- and micrometric-scaled emulsions.
Therefore, the study of particle formulation has to include the
knowledge of emulsion formation phenomena. Nano- and
microemulsion generation is very commonly performed with
such high-energy emulsification methods, particularly exploited
in polymeric materials.129,130 The formation of such nano- and
micrometric scaled particles is governed by directly controllable
formulation parameters, such as the quantity of energy and
nature of the components.
In the area of engineered nano- and microparticles of
polymer origin there is a vast area of possibilities for the
chemical composition. They can be divided into two broad
Figure 6. Possible locations of water-soluble drugs or other
compounds without (1) or with (2) electrostatic or ionic bonds and
lipophilic (3) or amphipathic (4) drugs in the phospholipid
membrane.
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classes: protein-based and non-protein-based nano- and
microparticles platforms. Non-protein-based templates include
PEG, poly(amidoamine) (PAMAM), dextran, chitosan, etc.131
4.1. Protein-Based Nano- and Microparticles. Among
of polymers systems, those based on proteins are very
promising ones. Proteins are a class of natural molecules that
have unique functionalities and potential applications in both
biological and material fields.132 Nano- and microstructures
derived from proteins, especially protein particles, are
biodegradable, nonantigenic, metabolizable, and can also be
easily amenable for surface modification and covalent attach-
ment of drugs and ligands.133,134
To develop protein-based templates, there are several criteria
to be followed: first, the novel matrix should be easy to obtain
with relatively low cost; second, the new template has to
maintain the cells’ viability and not cause any immunogenic
reactions; third, the protein-based platform should be stable
and keep its chemical and mechanical properties once it has
been delivered in vitro or in vivo; fourth, the drug molecules
should also be stable in this new material; and fifth, the
biodegradable rate of this new novel platform should be slower
than that of the drug molecule release rate.135
A variety of proteins have been used and characterized for
drug delivery, such as albumin,136−138 silk fibroin (SF),139,140
casein,141,142 collagen,143,144 and gelatin.145−147
The serum albumin protein has been one of the most
extensively studied and applied in the preparation of nano- and
microparticles because of its availability, relative low cost,
stability, and unusual ligand-binding properties. For this reason,
its main characteristics will be pointed out in this review.
Albumin is a globular protein, which is emerging as a versatile
protein carrier for drug targeting and for improving the
pharmacokinetic profile of bioactive compounds. This is the
most abundant plasma protein (35−50 g L−1 human serum)
with a molecular weight of 66.5 kDa.148 Like most of the
plasma proteins, albumin is synthesized in the liver and is
responsible for the transport of fatty acids and others lipids that
would otherwise be insoluble in the circulating plasma.149 The
three-dimensional (3-D) structure of human serum albumin
(HSA) has been elucidated by X-ray structure analysis.150,151
The approximate 3-D shape of HSA can be described as an
ellipsoid consisting of three flexible spheres in a row (domains
I, II, and III) and is illustrated schematically in Figure 7.
HSA is one of the smallest proteins present in blood plasma.
Both size and abundance explain the fact that so many
metabolic compounds and therapeutic drugs are transported by
this protein. The binding sites for metabolic substrates and
diagnostic as well as therapeutic drugs have been extensively
studied and reviewed.152,153 These properties as well as its
preferential uptake in tumor and inflamed tissue, its ready
availability, its biodegradability, and its lack of toxicity and
immunogenicity make it an excellent candidate for drug
delivery.152
The bovine serum albumin (BSA) is also a very used protein
in the preparation of microparticles due to the lower cost when
compared with the HSA. The primary structures of HSA and
BSA are homologous by 80%.154 Albumins are characterized by
a low content of tryptophan, glycine, and methionine and a
high content of cysteine (17 disulfide bonds and one sulfhydryl
group) and the charged amino acids (a.a.), aspartic and
glutamic acids, lysine, and arginine. The difference between the
two proteins is that, in HSA, some hydrophobic a.a. are
replaced by other hydrophobic residues, e.g., BSA holds two
tryptophan’s a.a. in its structure and HSA has only one.149,154
4.2. Preparation of Protein-Based Nano- and Micro-
particles. In the later of 1960s, Rhodes and co-workers were
the first investigators to produce microspheres from natural
macromolecules for medical applications.155 By slightly
modifying the method proposed by Zolle,156 they succeed in
producing HSA particles with a size bellow one micrometer.156
The particles were formed by heat denaturation of a water-in-
oil emulsion of albumin. However, the heat denaturation can be
harmful for the entrapped drugs or bioactive molecules. To
solve this problem, the heat denaturation was replaced by the
chemical cross-linking agents, such as glutaraldehyde. Never-
theless, this method yields microspheres with a short storage
life, low stability, and high toxicity. These issues motivate new
methods of microparticle manufacture in order to improve
protein stability, allow the further sterilization, and eliminate
the addition of cross-linking agents.
Two main groups of devices are used in the literature: the
rotor/stator devices, which appear in the first articles of nano-
and microparticles, and high-efficiency devices, including high-
pressure homogenizers and ultrasound generators.157 In
general, high-energy nano- or microemulsification methods
produced by homogenizer or ultrasound are widely employed
for polymeric nano- and microparticle generation. Comparing
the both techniques, it is possible to state that the limitations of
high-pressure homogenizers are related with the processed
fluid, which has the potential to pick up metal and oil
contaminants from the homogenizer pump and be further
contaminated by the pumps seals.
Suslick and co-workers pioneered sonochemical synthesis of
protein microspheres, where simple sonication of a protein
solution produces microcapsules filled with air or a nonaqueous
liquid.45 They were made of BSA and were filled with n-
dodecane, n-decane, n-hexane, cyclohexane, or toluene. The
synthesis was conducted under high-intensity ultrasonic probe
upon sonicating the precursor solution under air or O2. The
average diameter of the protein microspheres was 2.5 μm with a
narrow size distribution. Ultrasonic irradiation of HSA
generates similar microspheres to those of the BSA, and the
same was obtained for the protein microspheres of hemoglobin
(Hb).49
In-depth mechanistic studies revealed that mechanism of
proteinaceous microspheres preparation is a direct result of the
Figure 7. X-ray structure of HSA. Reproduced with permission from
ref 151. Copyright 1994 Elsevier.
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chemical effects of ultrasound irradiation on an aqueous
medium. Indeed, the microspheres formation is a combination
of two acoustic phenomena: emulsification and cavitation.
Ultrasonic emulsification is a well-known process and does
occur in this biphasic system being this phenomenon necessary
for microspheres formation. Nevertheless, in vortex mixing,
emulsification occurs but microspheres are not formed.
Consequently, emulsification by itself is not sufficient for
microspheres formation. Ultrasonic emulsification creates the
microscopic dispersion of the protein solution necessary to
form the shape of the proteinaceous microsphere shell.
However, ultrasonic irradiation of liquids produces acoustic
cavitation: the formation, growth, and implosive collapse of
bubbles creating transient hot spots with enormous peak
temperatures and production of free radicals. Aqueous
sonochemistry caused by the implosive collapse of bubbles
produces •OH and H• radicals and, in the presence of O2,
superoxide (O2
•−) and HO2
• radicals. •OH, O2
•−, and HO2
•
radicals are all potential protein cross-linking agents. Using
various trapping agents, they concluded that the important
oxidant involved in microsphere formation is superoxide.47,48
They proposed that the cysteine, which is present in BSA, HSA,
and Hb, is oxidized by the O2
•−. The microspheres are then
held together by protein cross-linking through disulfide bounds
from cysteine oxidation.
In a later publication, Suslick and Grinstaff reported on the
preparation of aqueous suspensions of air-filled proteinaceous
microbubbles.46 The synthesis involves the ultrasonic irradi-
ation of aqueous protein solutions in the presence of O2. Yields
and size distribution of HSA and BSA microbubbles were
determined as a function of various experimental parameters.
The ultrasound irradiation was conducted for 3 min.46 This
irradiation time is typical for the optimal formation of the
protein microspheres. It is worth mentioning that the difference
in the formation of the liquid- and air-filled bubbles is in the
position of the sonicator. In a typical synthesis of liquid-filled
protein microspheres, the organic liquid is layered over a 5% w/
v protein solution and the horn is positioned at the water/
organic interface. For air-filled microbubbles, the horn is placed
at the water/air interface.
Another approach has been developed about the mechanism
of microspheres formation with ultrasound systems.52 To probe
whether the sonochemical microsphere formation process is
more general and can be applied to proteins that do not contain
cysteine residues, an attempt was made employing this method
to streptavidin, which has no sulfur residues.52 They had
extended the sonochemical method to this non-sulfur-
containing protein and demonstrated the formation of protein
microspheres. Nevertheless, no microspheres were obtained
when the pH was kept at 7. However, when the pH was
lowered to 6.0, by adding a concentrated acidic solution,
microspheres were formed. According to the proposed
explanation, hydrophobic or thermal denaturation of the
protein after the initial ultrasonic emulsification assists in
microsphere formation. A contribution is provided by the
lowering of the pH, which helps to neutralize the basic COO−
edges, thus creating a more favorable hydrophobic environ-
ment. To verify whether this hypothesis is correct, a
poly(glutamic acid) protein was sonicated.52 This protein
carries only carboxyl groups on the side chain. Microspheres of
the poly(glutamic acid) were formed only at a pH lower than
4.5. Thus, the authors concluded that hydrophobic interactions,
which become more dominant in an acidic medium, are
responsible for the production of the microspheres in a
poly(glutamic acid) as well as in streptavidin.
In addition, sodium polyglutamate (SPG) microspheres have
also been reported that are stabilized by hydrogen-bonding
networks instead of covalent cross-linking.56 More specifically,
the dominant interaction between the polymer chains are a
n e t w o r k o f h y d r o g e n b o n d s o r i o n p a i r s :
[RCO2
−···M+···O2CR] in which M
+ = H+ or Na+.56
Gedanken and co-workers62 have synthesized microspheres
made of a few different proteins. The three proteins used were
BSA, green fluorescent protein (GFP), and cyan fluorescent
protein−glucose binding protein−yellow fluorescent fused
protein (CFP-GBP-YFP). The two synthesized microspheres
made of mixed proteins are BSA-GFP and BSA-(CFP-GBP-
YFP). The authors characterized the three possible arrange-
ments from the assembly of two different kinds of proteins in
microsphere structures. First, the two combined proteins form
the microspheres walls. Second, the first protein forms the
microspheres walls, and the second one is encapsulated inside
the liquid-filled proteinaceous microsphere bubble. Third, each
kind of protein forms one-protein microspheres.62
Recently, Silva et al.66 highlighted the insights on the
mechanism of protein microspheres formation using two
different proteins, namely BSA and SF from Bombyx mori. As
was previously referred, BSA is a globular protein. In contrast,
SF is a fibrous protein and is mainly composed of hydrophobic
a.a. without cysteine residues in its structure. The SF from
Bombyx mori is an insoluble protein, and its primary structure
has been determined to be composed dominantly of a six a.a.
residue motif, i.e., -Gly-Ala-Gly-Ala-Gly-Ser- (Figure 8).158−160
The authors report the influence of different ratios of
aqueous/organic phase and protein concentration on micro-
spheres production using BSA and SF. An increase on protein
concentration promotes ≈100% of yield on particles formation,
independently of aqueous/organic ratio used. It was proved
that the use of lower organic fraction leads to smaller sizes
particles. It was also found that these parameters demonstrate
to be an important tool to control the sizes of particles, ranging
from 300 to 1500 nm. The conformation assessment obtained
with Fourier transform infrared (FT-IR) analysis demonstrated
a change on the secondary structure of SF upon sonication
treatment, presenting an increase on the amount of β-sheet.
Conversely, the sonochemical treatment did not affect the
secondary structure of the globular protein, BSA.
Based on these different sonochemical approaches to
synthesize protein microspheres, a multitude of parameters
Figure 8. Three-chain layer of a polypeptide GAGAGS model.
Reproduced with permission from ref 161. Copyright 2001 American
Chemical Society.
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should be controlled as well as the physicochemical protein
characteristics to determine the main mechanism of protein
microspheres formation for each protein in particular.
Cavaco-Paulo and co-workers67 further extended the
sonochemical method to new engineering peptides, with a
range of sizes and sequences, to highlight the mechanism of
proteinaceous microspheres formation. It was reported the
importance of some a.a. residues and their arrangement in
peptide construction in respect to obtain microspheres with
adjustable properties to cover a wide range of applications. The
authors proved that the larger peptides with separated and clear
hydrophobic and hydrophilic areas lead to small and more
stable spheres.
4.3. Biological Activity of Protein-Based Nano- and
Microparticles. A related effort by Suslick and Wong was the
biological activity of microspheres formed with Hb.49 The
microspheres of Hb were filled with air and are described as
having many of the ideal characteristics needed for use as blood
substitute. The results of the oxygen binding have shown that
Hb microspheres can bind and release oxygen at the same
oxygen pressures as native Hb. The authors have calculated the
oxygen-carrying capacity of the Hb microbubbles and found
that for O2-filled microbubbles it is greater by 50% than whole
blood (0.32 mL of O2 per mL of microbubble versus 0.2 mL of
O2 per mL of blood).
49
Later, Avivi and Gedanken performed two other inves-
tigations probing the biological activity of proteinaceous
microspheres.55,57 In the first, it was found that unlike a
denaturation process, where the biological activity of the
protein is destroyed, the sonochemical process leading to the
microspherization of a protein reduces its biological activity but
does not destroy it. Avidin microspheres are still active after the
sonochemical process. Thus, it was verified that avidin
microspheres have the ability to bind biotin, but to a lesser
degree than the native protein.55 In a second study related also
to the biological activity of proteinaceous microspheres, Avivi57
formed microspheres of α-amylase (1,4-α-D-glucanohydrolase,
endoamylase), a protein known to hydrolyze starch, glycogen,
and related polysaccharides by randomly cleaving the internal
α-1,4-glucosidic linkages. Microspheres of α-amylase were
compared for their catalytic activity with those of the native
protein. They concluded one more time that the sonochemical
method does not destroy the enzymatic activity of the
microspheres. In this research, it was demonstrated that the
sonication leading to the modification into microspheres of two
enzymes, α-amylase and α-chymotrypsin, is not a denaturation
process. The protein microspheres are catalytically active, but
their reactivity is reduced as compared to the native protein.
More recently, it was developed a new methodology to
recover the biological function of protein.68 The refolding of
ribonuclease A (RNase A) microspheres, assisted by protein
disulfide isomerase, is highlighted in this study. The ultrasound
application was shown to induce a loss of 35% of RNase A
enzymatic activity when compared to the native RNase A, and
protein disulfide isomerase was able to restore it.68 Moreover,
the application of protein disulfide isomerase on RNase A
microspheres emulsion, in the presence of appropriate oxidative
environment, suggested the refolding of microspheres into the
aqueous medium by a protein disulfide isomerase induced
structural change.
4.4. Protein Nano- and Microparticles Stability. When
protein nano- and microparticles are used as the DS, their
stability becomes a major concern, mainly against aging and
aggregation. This issue has been studied for quite a long time,
and a variety of factors are known to influence it. These factors
include, but are not limited to, particle size distribution,
surfactant type and concentration, aqueous solubility of the
dispersed phase, temperature, surface tension, and ionic
strength.162 To investigate the stability of prepared particles,
a program of study should be performed to measure in
appropriate interval time their physical stability.
The most important parameter affecting the stability of
microspheres is their size and its distribution, which can be
determined by PCS. If the microspheres are even slightly
soluble in the aqueous phase, mass transfer will occur from the
smaller microspheres to the larger ones. This phenomenon,
Ostwald ripening, was first theorized by Ostwald in 1901.163
Ripening usually occurs in solution due to the lack of
monodispersity of microspheres. If all microspheres have the
same size, ripening does not occur. The protein microspheres
prepared by sonication usually have a broad size distribution
due to the disruption of acoustic sound. This limitation can be
overturned by the addition of a different surfactant.
The surfactant, also called a tensioactive agent, is frequently
employed for the dispersion of one phase in another immiscible
phase and for the stabilization of obtained emulsion. It reduces
the surface tension of continuous phase, avoids the coalescence
and agglomeration of drops, and stabilizes the emulsion. A
suitable surfactant should be able to give microspheres of a
regular size with small size distribution, guaranteeing a more
predictable and stable drug release. There are four different
types of surfactant classified by the nature of the hydrophilic
part of molecule: anionic, cationic, amphoteric, and nonionic.
It is unrealistic to find a single surfactant that properly works
for all different processes. Different formulations impose
different requirements on stabilizers.164−167 Furthermore,
differences in the surfaces characteristics of drug would require
different properties of stabilizers.168
The amount of stabilizer used will also have an effect on the
properties of the micro- and nanoparticles. Most importantly, if
the concentration of the stabilizer is too low, aggregation of the
polymer droplets will occur and little if any particles will be
recovered. Alternatively, if too much of the stabilizer is used,
the drug incorporation could be reduced due to interaction
between the drug and stabilizer. However, when the stabilizer
concentration is between the “limits”, adjusting the concen-
tration can be a means of controlling particle size.169
Recently, it was demonstrated the importance of adding
stabilizers to obtain a monodisperse population of proteina-
ceous microspheres by sonochemical synthesis.70 Several
stabilizers were studied, and the poly(vinyl alcohol) (PVA)
was shown to be the best choice to obtain BSA and HSA
microspheres with small size, homogeneous dispersion, and
high stability. The authors also proved that the presence of
PVA increased the entrapment efficiency of an anti-
inflammatory drug, piroxicam.
4.5. Protein-Based Nano- and Microparticles as
Delivery Systems. Another important issue is the possibility
of using such devices as DDS for different diseases. Since the
first reports on the preparation of uniformly sized albumin
microspheres in the early 1970s, these biodegradable,
biocompatible particles have found various applications.
Initially conceived as a diagnostic tool,170 albumin particles
have been utilized as drug-carrier systems.171
In general, the polymeric DS release bioactive agents by the
following mechanisms:172,173 diffusion, chemical reaction, or
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solvent activation. The release of a bioactive agent from a
particle is primarily controlled by diffusion of the bioactive
agent through the polymer.174 For biodegradable polymers,
degradation is a chemical process, whereas erosion is a physical
phenomenon dependent on dissolution and diffusion process.
As soon as the bioactive agent-containing polymer (A) comes
into contact with the external liquid environment, it enters the
polymer matrix (B), resulting in a swelling process, which
allows the diffusion of the bioactive agent into the external
environment174 (C), as illustrated in Scheme 1.
Factors influencing the release rate include the molecular size
of the bioactive agent and the entrapped percentage into the
nano- and microparticle as well as polymer composition and
the dimensions and shape of the particles.172
Regarding the release profile, strategies to control or render
it more adequate for a particular application by means of
modifying parameters, such as the surface (by coating, chemical
modification, and use of surfactants), or creating dual-release
systems (layers of materials that can incorporate different
molecules) can greatly improve the properties of several
materials. With this, the obtained microspheres can be changed
to increase their stability as well as to target an organ or a tissue.
The availability of numerous exploitable side groups in
proteins, such as amine, hydroxyl, thiol, and carboxyl groups,
makes it possible to use conjugation routes on prefabricated
particles.
The encapsulation of the antibiotic tetracycline (TTCL) in
BSA microspheres by the sonochemical method was success-
fully obtained by Avivi and Gedanken.54 The amount of TTCL
entrapped in microspheres was determined, and the maximum
TTCL entrapment capacity was found to be 65%. They
concluded that the percentage of the entrapped drug in the
BSA microspheres increased with the increase in the
concentration of the TTCL in the original solution.
Furthermore, the antimicrobial activity of the TTCL into
BSA microspheres was tested on two bacterial strains that are
sensitive to TTCL, demonstrating an inhibition zone around
both bacteria of 30 mm. However, they also concluded that the
TTCL trapped within the microsphere and released to the
medium is equally active as the TTCL freed from the
microspheres by heating. Both sonochemically treated TTCLs
are active as antimicrobial agents to the same degree as TTCL
that was not sonochemically treated. In the same research
group the proteinaceous microspheres of BSA containing an
anticancer drug (Taxol) were produced and characterized, and
the maximum entrapment capacity of Taxol was found to be
above 90%.175 The anticancer activity of the BSA microspheres
containing Taxol was also tested. The Taxol encapsulated in the
BSA microspheres and organic solvent were released from the
microspheres after 24 h of incubation at the desired locality of
the cancer cells. They found that influence of the Taxol
microspheres on the cancer cells was different from original
Taxolthe increase in the apoptotic cells was greater than the
increase in the G2-M phase of the cell cycle. The reason for the
behavior of the Taxol-loaded microspheres is related to the
organic solvent (mesytilene) that caused the death of some of
the cancer cells. Later, the gemcitabine, which is also an
anticancer drug, was encapsulated on BSA microspheres
(BSA−Gemzar).61 The maximum entrapment capacity of
Gemzar was found to be above 30%. The BSA−Gemzar
composite was examined for its anticancer activity (in vitro) in
renal cancer cells (RCC, 786-O cells) using [3H]thymidine
incorporation assays. The authors noted that the influence of
the Gemzar-loaded microspheres on the cancer cells was
significantly greater than that of an equimolar concentration of
Gemzar. They also believed that the rapid release of the drug at
the target site may be due to the proteases present at the target
environment. However, the precise mechanism for the release
of drugs at the targeted environment was not clarified by the
authors.
Recently, the benefits of encapsulated oil were verified by
Silva et al.69 The authors reported a novel approach using
proteinaceous microspheres of BSA, HSA, and SF containing
different organic solvents, namely n-dodecane, mineral oil, and
vegetable oil, to reduce the activity of human neutrophil
elastase (HNE) found in high levels on chronic wounds. The
ability of these devices to inhibit HNE was evaluated using
porcine pancreatic elastase (PPE) solution as a model of wound
exudates. The results obtained indicated that the level of PPE
activity can be tuned by changing the organic solvent present
on different protein microspheres. Moreover, these proteina-
ceous microspheres were shown to be important carriers of
elastase inhibitors causing no cytotoxicity in human skin
fibroblasts in vitro. These devices demonstrate an innovative
way to control the imbalance of elastase/antielastase found in
chronic wounds.
The entrapment of an anti-inflammatory drug, piroxicam,
was also achieved, using BSA and HSA microspheres.70 The
entrapment efficiency of piroxicam into BSA and HSA
microspheres was assessed and shows that PVA promotes the
increase of drug incorporation efficiency in both types of
proteinaceous devices prepared (≈80% with PVA and ≈50%
without PVA). The work performed included the determi-
nation of the release kinetics of piroxicam from proteinaceous
microspheres in the presence of protease, indicating an
anomalous drug transport mechanism (diffusion and polymer
degradation). In the presence of higher protease concentration,
BSA microspheres exhibit case II transport, leading to zero-
order release (polymer degradation). The authors proved that
the kinetics of piroxicam entrapped in BSA or HSA
microspheres release mechanism is dependent on the protein
and on protease concentration. Furthermore, these proteina-
ceous devices did not show cytotoxicity against human skin
fibroblasts in vitro , for range concentrations below 300 mg L−1,
greatly supporting their potential application in the treatment
of inflammatory diseases.
Scheme 1. Schematic of the Release of Entrapped Drug or
Bioactive Agents from Biodegradable Polymeric Particlesa
aWhen the polymer device incorporating the bioactive agent (A) is
inserted into the environment, the fluid from the surrounding medium
enters the particle (B), causing swelling of the device. The fluid creates
diffusion channels (C), and the incorporated active agent is released to
the external environment. The degradation of material device occurs
over time or by chemical reactions (e.g., enzymatic attack and chemical
reactions on particular polymeric sites).
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Suslick and co-workers56 reported on a noncovalent,
electrostatic layer-by-layer (LBL) modification that successfully
targets protein microspheres to the integrin receptors that are
overexpressed in several tumor types. They determined the
efficacy of the RGD-modified microspheres in tumor targeting
by using HT29 tumor cells in vitro. HT29 cells are human
colon tumor cells which are known to overexpress integrin
receptors. For the targeting experiments, microspheres were
synthesized with Nile red fluorescent dye in vegetable oil in
their core. The fluorescence results demonstrate that binding of
RGD-modified microspheres is increased relative to the
unmodified ones. Suslick has found that these negatively
charged vesicles are excellent templates for LBL electrostatic
adhesion, which opens a new tool for both targeted imaging
and targeted drug delivery.
Multilayer deposition of polyelectrolytes onto air-filled
microbubbles is an attractive strategy to design targeted
particles. Cavalieri et al.59 report the synthesis of stable and
functional microbubbles, coated with chemically reduced
lysozyme, using high-intensity ultrasound in aqueous solution.
In order to demonstrate the possibility of surface functionaliza-
tion of lysozyme microbubbles, which is of importance in
targeted drug delivery, they adsorbed a polyelectrolyte on the
surface of the microbubbles. Lysozyme air-filled microbubbles
are positively charged colloidal particles and provide a good
template for assembly of polyelectrolyte multilayer using the
LBL approach. Two layers of poly(styrenesulfonate)/poly-
(allylamine hydrochloride) were assembled on the lysozyme
shell, indicating the possibility of adsorbing potential drugs
and/or biolabels on the surface of these microbubbles for
therapeutic and diagnostic applications.
Another approach of proteinaceous microspheres is their
application onto textile support. In fact, the prolonged contact
time of a drug with a body tissue, through the use of wound
dressings, can significantly improve the performance of many
drugs. These improvements range from better treatment of
local pathologies to improved drug bioavailability and
controlled release to enhanced patient compliance.176 Fur-
thermore, dressings that will deliver an active substance to a
specific target site in a controlled fashion for a sustained period
could help solve or minimize the noncompliance patients. In
this highlight, the use of DS attached onto textiles-based wound
dressings is being exploited for the treatment of several
diseases.
There are a variety of methods for the attachment of the DS
onto several dressings. The sonochemical method appears as
one of the most effective methods, once that it is possible to
produce and attach the microspheres to fibers by one-step
reaction.
BSA and casein microspheres have been attached to cotton
and polyester fabrics using sonochemical radiation.177 Proteina-
ceous microspheres bound to polyester remain linked to the
fabric even after repeated washings in a washing machine,
suggesting that these coated fibers can be used either for one-
time application or for repeated use.
Gouveia178 also demonstrate the potentialities of sonochem-
ical methodology to develop a coating process based on BSA/L-
cysteine (L-Cys) microspheres on different textile materials,
namely 100% of cotton, wool, polyester, polyamide, cellulose
acetate, and viscose. The microspheres developed by this
process evidence antimicrobial property by themselves due to
the addition of L-Cys. The author performed the antibacterial
assays against S. aureus and K. pneumonia. The results revealed
the antibacterial effect of a BSA + L-Cys microsphere-coated
cotton textile fabric, both for Gram-positive and -negative
bacteria, by the inhibition zone located under the textile.
Therefore, the antimicrobial functionalization of the fibers with
L-Cys microspheres is a promising new approach that can also
diminish bacteria resistance.
Recently, it was reported the use of an anti-inflammatory
drug, piroxicam, sonochemical entrapped on BSA microspheres
and attached onto cotton and nonwoven gauzes by two
different methodologies (incubation and sonochemical meth-
odology).179 The authors proved that the highest release was
achieved when the attachment process was performed by the
sonochemical method. The short time treatment (3 min)
improves the mass transport effects enhancing the micro-
spheres attachment. The capacity of ultrasound to attach the
microspheres to gauzes was made by one-step reaction,
providing a reduction in the products consumption, shorter
process time, and a greater uniformity of the treatment.
Furthermore, the authors prove that the release of piroxicam
entrapped in BSA microspheres was shown to be dependent on
the gauzes structure, demonstrating a faster and higher
concentration of piroxicam released when the proteinaceous
microspheres were attached on nonwoven gauzes. This work
shows the ability of the functionalized biomaterial to deliver the
pharmaceutical agent.
The major advantages of the sonochemical methodology in
comparison with other techniques that are commonly used to
incorporate microspheres/microcapsules onto textile materials
are the nontoxicity both to the potential users and to the
environment and the possibility of being carried out in a simple
step process with short reaction time and without using cross-
linking agents such glutaraldehyde or epoxy resins that are
normally required to produce microspheres or to bind them
onto the textile materials.
5. MAJOR REMARKS AND FUTURE OUTLOOK
The rapidly developing field of nano- and microstructured
synthesis constantly attracts new methods and solutions for
further improving the process performance.
The usefulness of sonochemical synthesis as a synthetic tool
resides in its versatility. In this review it was highlighted the use
of ultrasound sources to produce different nano- and
microparticles starting from phospholipids and polymeric
based proteins. The progress achieved on the synthesis of
lipidic and polymeric nano- and microstructures has been
accompanied by the parallel exploitation of these materials in
various fields, among them the controlled release. The
sonochemical method has been further extended to the
applications of these delivery devices designed to be textile-
based wound dressings.
There are still some challenges left to be overcome for
further development delivery-based platforms. The variety of
natural proteins encourages us to explore more naturally
existing proteins for versatile drug delivery, which can be
prepared by the sonochemical method.
Future developments for delivery devices can focus on the
enhanced site-specific drug delivery by using receptor-targeting
ligands, improve sustained drug release rates with enhanced
permeability and retention time, and minimize the undesirable
side effects.
Furthermore, there is a demand to obtain preparation
methods of the nano- and microparticles that are able to be
reproducible on an industrial scale.
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